GB2610311B - HLA class I-restricted T cell receptors against RAS with G12V mutation - Google Patents

HLA class I-restricted T cell receptors against RAS with G12V mutation Download PDF

Info

Publication number
GB2610311B
GB2610311B GB2211757.6A GB202211757A GB2610311B GB 2610311 B GB2610311 B GB 2610311B GB 202211757 A GB202211757 A GB 202211757A GB 2610311 B GB2610311 B GB 2610311B
Authority
GB
United Kingdom
Prior art keywords
mutation
restricted
hla class
cell receptors
receptors against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2211757.6A
Other languages
English (en)
Other versions
GB2610311A (en
GB202211757D0 (en
Inventor
Levin Noam
R Parkhurst Maria
J Lowery Frank Iii
A Rosenberg Steven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of GB202211757D0 publication Critical patent/GB202211757D0/en
Publication of GB2610311A publication Critical patent/GB2610311A/en
Application granted granted Critical
Publication of GB2610311B publication Critical patent/GB2610311B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
GB2211757.6A 2020-02-14 2021-02-12 HLA class I-restricted T cell receptors against RAS with G12V mutation Active GB2610311B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976655P 2020-02-14 2020-02-14
US202063060340P 2020-08-03 2020-08-03
PCT/US2021/017852 WO2021163477A1 (en) 2020-02-14 2021-02-12 Hla class i-restricted t cell receptors against ras with g12v mutation

Publications (3)

Publication Number Publication Date
GB202211757D0 GB202211757D0 (en) 2022-09-28
GB2610311A GB2610311A (en) 2023-03-01
GB2610311B true GB2610311B (en) 2025-07-09

Family

ID=74860482

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2211757.6A Active GB2610311B (en) 2020-02-14 2021-02-12 HLA class I-restricted T cell receptors against RAS with G12V mutation

Country Status (12)

Country Link
US (1) US20230082787A1 (https=)
EP (1) EP4103598A1 (https=)
JP (1) JP7735285B2 (https=)
KR (1) KR20220143875A (https=)
CN (1) CN115315441A (https=)
AU (1) AU2021220957A1 (https=)
BR (1) BR112022015897A2 (https=)
CA (1) CA3167382A1 (https=)
GB (1) GB2610311B (https=)
MX (1) MX2022009825A (https=)
TW (1) TWI902755B (https=)
WO (1) WO2021163477A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
WO2023232785A1 (en) * 2022-05-30 2023-12-07 Hs Diagnomics Gmbh Common tumor-specific t cell receptors
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170319638A1 (en) * 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
WO2019112941A1 (en) * 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
MX384919B (es) 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.
JP7185524B2 (ja) * 2015-09-15 2022-12-07 アメリカ合衆国 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
EP3684799A1 (en) 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170319638A1 (en) * 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
WO2019112941A1 (en) * 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against mutated ras
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Q. J. WANG ET AL, "Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors", CANCER IMMUNOLOGY RESEARCH, vol. 4, no. 3, 1 March 2116 (2016-03-01), pgs 204-214, US ISSN 2326-6066, doi:10.1158/2326-6066.CIR-15-0188, abstract *

Also Published As

Publication number Publication date
TW202140535A (zh) 2021-11-01
JP2023526149A (ja) 2023-06-21
GB2610311A (en) 2023-03-01
KR20220143875A (ko) 2022-10-25
CN115315441A (zh) 2022-11-08
EP4103598A1 (en) 2022-12-21
US20230082787A1 (en) 2023-03-16
MX2022009825A (es) 2022-10-13
JP7735285B2 (ja) 2025-09-08
TWI902755B (zh) 2025-11-01
GB202211757D0 (en) 2022-09-28
WO2021163477A8 (en) 2022-09-29
CA3167382A1 (en) 2021-08-19
AU2021220957A1 (en) 2022-09-01
BR112022015897A2 (pt) 2022-10-18
WO2021163477A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
GB2610311B (en) HLA class I-restricted T cell receptors against RAS with G12V mutation
GB2609760B (en) HLA Class I-restricted T cell receptors against RAS with G12D mutation
IL275031A (en) HLA type I antigenic T cell receptors against mutated RAS
GB2610069B (en) HLA class II-restricted T cell receptors against RAS with G12V mutation
SG11202002425PA (en) Hla class ii-restricted t cell receptors against mutated ras
GB2594192B (en) Fuel cell unit and fuel cell stack
EP3664157C0 (en) SOLAR CELL AND ITS MANUFACTURING METHOD
TWD176966S (zh) 充電器之部分
EP3381047A4 (en) BURNED MULTILAYER STACKS IN INTEGRATED CIRCUITS AND SOLAR CELLS
PL3430037T3 (pl) Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
EP3259066A4 (en) Device, platform, and assay for assessing cells
GB202305617D0 (en) Hla class ii-restricted dq t cell receptors against ras with g13d mutation
EP3487877A4 (en) USE OF THE ANTIBODY COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE CANCER ANTIBODIES IN THE TREATMENT OF CANCER
SG11202009216YA (en) Total afucosylated glycoforms of antibodies produced in cell culture
EP3874549A4 (en) HOLDER STRUCTURE FOR ENERGY STORAGE CELLS IN AN ENERGY STORAGE DEVICE
GB202019019D0 (en) T cell receptors and uses thereof
BR112015000651A2 (pt) dispositivos de armazenamento de energia com pelo menos um substrato policristalino poroso
EP3602645C0 (en) ULTRA-THIN PLASMONIC SOLAR CELLS, METHODS OF MAKING AND USE THEREOF
IL271012A (en) T cells with reduced surface fucosylation and methods of making and using the same
ES3063075T3 (en) Hla class ii-restricted drb t cell receptors against ras with g12v mutation
HK40085167A (en) Hla class i-restricted t cell receptors against ras with g12v mutation
HK40085166A (en) Hla class i-restricted t cell receptors against ras with g12d mutation
HK40085989A (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
BR112015017513A2 (pt) determinação de um conjunto de agrupamento de dispositivos móveis
TWI923548B (zh) 針對含有g12r突變之ras之hla第ii類限制性t細胞受體